Hematology

A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...

The FDA approved oral decitabine and cedazuridine (Inqovi) tablets with venetoclax for adults with newly diagnosed acute myeloid leukemia who are aged 75 years or older or have comorbidities that preclude...

In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.

A retrospective single-center study evaluates outcomes of patients refusing standard blood products in favor of directed “unvaccinated” donations.

In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.

In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

A phase 3 trial evaluated weekly marstacimab prophylaxis in adolescents and adults with hemophilia A or B with inhibitors.

Final phase 3 results assessed 5-year efficacy and safety of etranacogene dezaparvovec in adults with hemophilia B.

In a large global phase 3 trial, investigators evaluated whether adding the CD19-targeted monoclonal antibody tafasitamab to the established lenalidomide–rituximab regimen could improve outcomes for adults...